查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
减肥手术市场——增长、趋势、COVID-19 的影响和预测 (2023-2028)
市场调查报告书
商品编码
1190025

减肥手术市场——增长、趋势、COVID-19 的影响和预测 (2023-2028)

Bariatric Surgery Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在 2022 年至 2027 年的预测期内，减肥手术市场预计将以 5.7% 的复合年增长率增长。

对于市场而言，预计 COVID-19 大流行将产生重大影响。 诊断和外科行业受到全球封锁措施的影响，这些措施减少了公众流动性。 根据美国代谢与减肥外科医师协会 (ASMBS) 的说法，减肥手术被认为是一种非紧急手术，导致这些手术被搁置，成功率也在下降。 根据最近的一项研究，即 COVID-19 大流行期间医生和患者的减肥手术，2020 年 9 月，COVID-19 大流行期间的病态肥胖以及手术风险和并发症的增加导致减肥计划减少。虚拟会诊和远程医疗被认为适合继续进行。 肥胖人群容易受到心理和生理条件的影响，这阻碍了大流行性肥胖症的管理。 柳叶刀论文《2020 年 COVID-19 大流行期间和之后的减肥和代谢手术》指出，大流行将对肥胖治疗产生重大影响，使数百万儿童、青少年和成人面临合併症加重的风险。接受治疗，并且更有可能出现较差的 COVID-19 结果。 因此，大量的 COVID-19 阳性患者和对全球医疗保健系统的巨大影响是导致几种肥胖治疗药物下降的原因，从而对 2020 年和 2021 年的市场产生了负面影响。略有影响。

推动肥胖减肥手术市场增长的主要因素是人口中肥胖患病率上升以及 2 型糖尿病和心脏病患病率上升。 体内脂肪多的人更容易患糖尿病。 因此，患者在减肥手术中采取一定的措施来预防肥胖。 例如，根据世界卫生组织（WHO）2022年5月关于欧洲区域的报告，在世界卫生组织欧洲区域，超过60%的成年人、29%的年轻男孩和27%的年轻女孩超重或肥胖。并且根据根据该报告，超重和肥胖在该地区的非传染性疾病危险因素中排名第四，仅次于高血压、不健康饮食和吸烟。 此外，根据国际糖尿病联合会 2021 年 12 月的报告，2021 年全球约有 5.37 亿 20-79 岁的成年人患有糖尿病，到 2030 年这一数字将增加，预计将增至 6.43 亿。 因此，由于肥胖的高负担和肥胖风险因素的流行，预计将在预测期内推动减肥手术市场的增长。

此外，肥胖患病率的上升将增加对减肥手术的需求，这将有助于扩大市场。 根据世界卫生组织 2021 年 6 月的数据，2020 年有 3900 万五岁以下儿童超重或肥胖。 据估计，2019 年有 3820 万 5 岁以下儿童超重或肥胖。 超重和肥胖曾经被认为只是高收入国家的问题，但现在在低收入和中等收入国家尤其是城市地区很普遍。 自 2000 年以来，非洲五岁以下超重儿童的比例增加了近 24%。 根据世界肥胖联盟发布的 2022 年 3 月世界肥胖地图集，到 2030 年，全球将有 10 亿人肥胖，其中包括五分之一的女性和七分之一的男性。我预测。 因此，由于肥胖患病率上升和手术需求增加，预计减肥手术市场将在预测期内增长。

此外，市场的扩张得到了主要市场参与者采取的各种战略的支持，例如资助研发以扩大减肥手术的范围。 例如，2021 年 6 月，总部位于辛辛那提的 Standard Bariatrics, Inc. 开发了 Titan SGS，这是同类产品中的首创设计，可让外科医生进行袖状胃切除术，这是治疗肥胖病的顶级减肥手术。6，2021 年5 月，总部位于辛辛那提的 Standard Variatrix 开发了 Titan SGS，以帮助外科医生进行袖状胃切除术，这是针对肥胖症的顶级减肥手术。 此外，2021 年 6 月，Standard Bariatrics 获得了 3500 万美元的 B 系列资金，以加速其第一个用于袖状胃成形术的减肥手术平台的开发和商业化。

因此，很明显，糖尿病和肥胖患病率的上升将在未来几年显着推动减肥手术市场。 然而，高昂的手术费用可能会抑制市场增长。

减肥手术市场趋势

胃球囊有望在植入器械领域保持高复合年增长率

胃气球，也称为胃内气球 (IGB) 或胃气球，是一种可膨胀的医疗工具，可瞬间插入胃中以帮助减轻体重。 新产品的推出、患者意识的提高、与减肥手术中心的合作以及製造优化以提高运营槓桿是推动球囊需求的一些因素。

美国批准的胃气球包括 ReShape Duo Balloon 和 ORBERA Balloon。 2019年5月，Spatz Medical宣布其新推出的Spatz3球囊在一系列临床试验中获得美国FDA批准，其疗效明显优于市场上任何不可调节球囊。 然而，市场参与者正在采用多种不同的策略，例如筹款和产品发布流程。 胃排空气球製造商 Allurion Technologies 已筹集了 3400 万美元的额外资金，以加速 Elipse Balloon 的商业化努力和进入美国市场。 因此，由于上述原因，胃气球部分有望在预测期内推动。

北美主导市场，预计在预测期内也会如此

北美预计将在整个预测期内主导整个市场。 这是由于整个地区的肥胖人数不断增加。 它还受到该地区更好的医疗保健基础设施的可用性以及减肥手术意识的提高的推动。 在北美地区，美国占据了最大的市场份额。 根据美国疾病控制与预防中心 (CDC) 2022 年 5 月的数据，从 2017 年 3 月到 2020 年 3 月，41.9% 的美国人肥胖。 美国的肥胖患病率从 30.5% 上升到 41.9%。 同期，严重肥胖的患病率从 4.7% 上升到 9.2%。 CDC 已将肥胖确定为美国第一大可预防死因，也是全球和美国慢性病的主要原因之一。 与肥胖相关的疾病，称为合併症，包括心血管疾病、糖尿病、肌肉骨骼疾病和某些癌症。

根据2021年6月发布的美国国家健康统计报告，在20岁以上的成年人中，肥胖患病率为41.9%，重度肥胖患病率为9.2%，糖尿病患病率为14.8%。 预计人口中肥胖患病率的增加将推动美国的减肥手术市场。 此外，该国拥有完善的医疗保健基础设施以及众多市场参与者的存在，预计将在预测期内推动市场增长。 例如，2020 年 9 月，强生医疗器械公司旗下的 Ethicon 推出了 ECHELON ENDOPATH Staple Line Reinforcement (SLR)，这是一种旨在减少减肥手术期间可能发生的并发症的支撑装置。现已上市销售。

此外，预计该地区主要市场参与者推出的产品将推动市场增长。发布了该设备。 POWERSEAL 设备可用于多种形式的外科手术，包括减肥手术。 同样，2021 年 6 月，强生医疗器械公司旗下的 Ethicon 推出了 ENSEAL X1 Curved Jaw Tissue Sealer，用于结直肠、妇科、减肥手术和胸部手术。

这样一来，美国肥胖症的高患病率、越来越多地采用减肥手术以及不断上升的保险覆盖率将导致预测期内减肥手术市场的增长有望领先。

减肥手术市场竞争分析

减肥手术市场竞争适中，由几家主要参与者组成。 就市场份额而言，几家主要参与者目前主导着市场。 随着患者意识水平的提高和肥胖人口的增加，预计未来几年其他几家中小企业也将进入市场。 主要参与者包括 Medtronic PLC、Ethicon Inc.、Apollo Endosurgery Inc. 和 Intuitive Surgical Inc.。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动力
    • 肥胖患者增加
    • 2 型糖尿病和心脏病的患病率
    • 政府控制肥胖的努力
  • 市场製约因素
    • 手术费用高
    • 发展中国家和欠发达国家缺乏知识和意识
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按设备
    • 辅助设备
      • 缝合装置
      • 关闭装置
      • 装订装置
      • 拖钓者
      • 其他辅助设备
    • 植入式设备
      • 胃带
      • 电刺激器
      • 胃气球
      • 胃瘘
    • 其他设备
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 西班牙
      • 意大利
      • 法国
      • 其他欧洲
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Medtronic PLC
    • Ethicon Inc.（Johnson and Johnson）
    • Apollo Endosurgery Inc.
    • Aspire Bariatrics Inc.
    • Intuitive Surgical Inc.
    • B. Braun Melsungen AG
    • Olympus Corporation
    • The Cooper Companies
    • Conmed Corporation
    • Cousin Biotech
    • Cook Medical

第7章 市场机会与今后动向

简介目录
Product Code: 52146

The Bariatric Surgery Market is poised to grow at a CAGR of 5.7% during the forecast period, 2022-2027.

On the market, the COVID-19 pandemic is anticipated to have a significant effect. The diagnostic and surgical industries have been impacted by the global lockdown measures, which have also decreased public mobility. As per the American Society for Metabolic & Bariatric Surgery (ASMBS), bariatric surgeries are considered non-emergent procedures, as a result, these procedures were on hold and their success rate has declined. As per a recent study 'Bariatric Surgery During the COVID-19 Pandemic the Perspective of Physicians and Patients', in September 2020, virtual consultation and telemedicine were considered suitable to continue weight loss programs, as the risks and complications of morbid obesity and surgery during the COVID-19 pandemic were high. The obese population is vulnerable to psychological and physiological conditions, which have hurt the pandemic's management of obesity. According to the Lancet article 'Bariatric and metabolic surgery during and after the COVID-19 pandemic' 2020, the pandemic has had a significant impact on obesity treatment, putting millions of children, adolescents, and adults at risk for worsening comorbidities, limiting their access to care and raising their chances of having poor COVID-19 outcomes. Thus, a large number of COVID-19 positive patients and its significant effect on healthcare systems across the world are responsible for the decline in several bariatric procedures and thereby negatively impacted the market in 2020 and slightly in 2021.

The major factors attributing to the growth of the bariatric surgery market are an increase in obesity among people and a rising prevalence rate of Type 2 diabetes and heart diseases. People with more fat in their bodies are highly likely to be affected by diabetes. Hence, patients are taking certain measures to prevent obesity with bariatric surgeries. For instance, according to the World Health Organization (WHO) May 2022 report on the European region, in the WHO European Region, over 60% of adults and 29% of boys and 27% of girls who are children are overweight or obese and also, as per the same report, overweight and obesity rank fourth among the risk factors for non-communicable diseases in the region, after high blood pressure, unhealthy eating, and cigarette use. Further, according to the December 2021 report of the International Diabetes Federation, it is estimated that about 537 million adults in the age group of 20-79 years were living with diabetes in 2021 across the world and this number is projected to increase to 643 million by 2030. Hence, owing to the high burden of obesity and the increasing prevalence of risk factors for obesity are expected to fuel growth in the bariatric surgery market over the forecast period.

Additionally, the rising prevalence of obesity increases the demand for bariatric surgery, which helps the market expand. According to the World Health Organization in June 2021, there were 39 million under-five years old kids who were overweight or obese 2020. In addition, it was estimated that 38.2 million kids under the age of 5 were overweight or obese in 2019. Overweight and obesity, once thought to be a problem only in high-income nations are now becoming more prevalent in low- and middle-income nations as well, especially in urban areas. Since 2000, there has been a nearly 24% increase in the proportion of under-five overweight children in Africa. Moreover, World Obesity Atlas March 2022 published by the World Obesity Federation, predicts that by 2030, one billion people worldwide, including one in five women and one in seven men, will have obesity. As a result, the market for bariatric surgery is anticipated to grow over the projection period due to the rising prevalence of obesity and the increased need for the procedure.

Furthermore, the market expansion is supported by a variety of strategies employed by the major market players, such as funding for research and development to broaden the scope of bariatric surgery. For Instance, In June 2021, Cincinnati-based Standard Bariatrics, Inc., developed the Titan SGS, a first-of-its-kind design that offers surgeons to perform sleeve gastrectomy, the top bariatric surgical procedure for obesity disease. Additionally in June 2021, to expedite the development and commercialization of their first bariatric surgical platform for sleeve gastroplasty, Standard Bariatrics has secured USD 35 million in Series B funding.

Therefore, it is clear that the growing prevalence of diabetes and obesity will significantly drive the market for bariatric surgery over the upcoming years. However, the high cost of surgery may restrain the market growth.

Bariatric Surgery Market Trends

Gastric Balloons is Expected to Record a High CAGR in the Implantable Device Segment

A gastric balloon also referred to as an intragastric balloon (IGB) or a stomach balloon, is an inflatable medical tool that is momentarily inserted into the stomach to aid in weight loss. The introduction of new products, an increase in patient awareness, collaboration with bariatric surgery centers, and manufacturing optimization to increase operating leverage are some of the factors that are driving the demand for balloons.

According to the study titled "Endoscopic intragastric balloon: a gimmick or a viable option for obesity?" published in the Annals of Transitional Medicine in March 2020, the Orbera gastric balloon results in a pooled total body weight loss (TBWL) of 13.16% after 6 months. Additionally, there was a 26.9 percent excess weight loss compared to controls. Thus, the efficacy of the gastric balloon to treat obesity and help in reducing weight supports the market growth.

Some of the approved Gastric Balloons in United States include the ReShape Duo Balloon and the ORBERA Balloon. In May 2019, Spatz Medical announced that its newly launched Spatz3 balloon is significantly more effective than any non-adjustable balloon in the market as approved by United States FDA in a series of clinical trials. However, market players have employed several different strategies such as the funding and product launch processes. Manufacturer of gastric weight-loss balloons Allurion Technologies has increased its funding by USD 34 million to accelerate its commercialization efforts and entry into the U.S. market for its Elipse Balloon. Thus, due to the above-mentioned reasons, the gastric balloon segment is expected to propel over the forecast period.

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America is expected to dominate the overall market throughout the forecast period. This is due to the increasing number of obese populations across the region. Another driving factor is the availability of better healthcare infrastructure in the region and the rising awareness of bariatric surgery. In the North American region, United States holds the largest market share. According to the Centers for Disease Control and Prevention (CDC) in May 2022, from March 2017 to March 2020, 41.9 percent of Americans were obese. The prevalence of obesity in United States increased from 30.5 to 41.9 percent. The prevalence of severe obesity rose from 4.7% to 9.2% during the same period. The CDC has identified obesity as a leading cause of preventable death in United States, and it is one of the leading causes of chronic diseases both worldwide and in United States. Obesity-related disorders, known as comorbidities, include cardiovascular diseases, diabetes, musculoskeletal disorders, and some cancers.

As per United States, National Health Statistics Reports published in June 2021, among adults aged 20 and over, the prevalence of obesity was 41.9%, severe obesity was 9.2%, and diabetes was 14.8%. The increase in the prevalence of obesity among the population is expected to drive the bariatric surgery market in United States. Furthermore, the presence of an established healthcare infrastructure along with the presence of a large number of market players in the country is expected to boost market growth over the forecast period. For instance, in September 2020, Ethicon, part of Johnson & Johnson Medical Devices Companies, launched ECHELON ENDOPATH Staple Line Reinforcement (SLR), a buttressing device designed to reduce potential complications during bariatric procedures

Furthermore, product launches by the key market players in the region are expected to boost the market growth For Instance, in September 2021, Olympus launched the POWERSEAL advanced bipolar surgical energy devices to Strengthen its Surgical Portfolio. The POWERSEAL devices can be used in numerous forms of surgical intervention including bariatric surgical procedures. Similarly, in June 2021, Ethicon, part of the Johnson & Johnson Medical Devices Companies launched the ENSEAL X1 Curved Jaw Tissue Sealer for colorectal, gynecological, bariatric surgery, and thoracic procedures.

Thus, the high prevalence of obesity and the increasing adoption of bariatric surgeries in United States, along with increasing insurance coverage, are expected to drive the bariatric surgery market during the forecast period.

Bariatric Surgery Market Competitive Analysis

The bariatric surgery market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and increasing obese population, few other smaller players are also expected to enter into the market in the coming years. Some of the major players of the market are Medtronic PLC, Ethicon Inc., Apollo Endosurgery Inc., and Intuitive Surgical Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Obesity Patients
    • 4.2.2 Prevalence Rate of Type 2 Diabetes and Heart Diseases
    • 4.2.3 Government Initiatives to Curb Obesity
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Surgery
    • 4.3.2 Lack of Knowledge and Awareness in Developing and Underdeveloped Countries
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Device
    • 5.1.1 Assisting Devices
      • 5.1.1.1 Suturing Device
      • 5.1.1.2 Closure Device
      • 5.1.1.3 Stapling Device
      • 5.1.1.4 Trocars
      • 5.1.1.5 Other Assisting Devices
    • 5.1.2 Implantable Devices
      • 5.1.2.1 Gastric Bands
      • 5.1.2.2 Electrical Stimulation Devices
      • 5.1.2.3 Gastric Balloons
      • 5.1.2.4 Gastric Emptying
    • 5.1.3 Other Devices
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 Spain
      • 5.2.2.4 Italy
      • 5.2.2.5 France
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Medtronic PLC
    • 6.1.2 Ethicon Inc. (Johnson and Johnson)
    • 6.1.3 Apollo Endosurgery Inc.
    • 6.1.4 Aspire Bariatrics Inc.
    • 6.1.5 Intuitive Surgical Inc.
    • 6.1.6 B. Braun Melsungen AG
    • 6.1.7 Olympus Corporation
    • 6.1.8 The Cooper Companies
    • 6.1.9 Conmed Corporation
    • 6.1.10 Cousin Biotech
    • 6.1.11 Cook Medical

7 MARKET OPPORTUNITIES AND FUTURE TRENDS